Adele Testi
University of Milan
20 Papers
175 Citations
Adele Testi is an academic researcher from University of Milan. The author has contributed to research in topics: Medicine & Cancer research. The author has an hindex of 10, co-authored 16 publications.
Chat about Author
Papers
First‐line therapy with dacomitinib, an orally available pan‐HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open‐label, single‐arm, single‐centre, phase 2 study
Andrea Necchi,Salvatore Lo Vullo,Federica Perrone,Daniele Raggi,Patrizia Giannatempo,Giuseppina Calareso,Nicola Nicolai,Luigi Piva,Davide Biasoni,Mario Catanzaro,Tullio Torelli,Silvia Stagni,Elena Togliardi,Maurizio Colecchia,Adele Busico,Annunziata Gloghini,Adele Testi,Luigi Mariani,Roberto Salvioni +18 more
TL;DR: To harness the frontline therapy in advanced penile squamous cell carcinoma (PSCC), for which chemotherapy exerts moderate activity but poor efficacy, Dacomitinib is an irreversible, pan‐epidermal growth factor receptor (HER) inhibitor.
86
B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology
TL;DR: Within the provisional borderline categories for lymphoma cases that demonstrate overlapping clinical, morphological, and/or immunophenotypic features between well-established entities, there are cases combining features of primary mediastinal large B-cell lymphoma and classical Hodgkin lymphoma.
68
Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists
Antonino Carbone,Gerardo Botti,Annunziata Gloghini,Gianni Simone,Mauro Truini,Maria Pia Curcio,Patrizia Gasparini,Anita Mangia,Tiziana Perin,Sandra Salvi,Adele Testi,Paolo Verderio +11 more
TL;DR: The staining and interpretative reproducibility of the HER2 SISH assay was evaluated at five laboratories and SISH results with other in situ hybridization (ISH) methods were compared.
43
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
Anna Dodero,Anna Guidetti,Alessandra Tucci,Francesco Barretta,M. Novo,L. Devizzi,Alessandro Re,Angela Passi,Alessio Pellegrinelli,Giancarlo Pruneri,Rosalba Miceli,Adele Testi,Martina Pennisi,M. C. Di Chio,Paola Matteucci,C. Carniti,Fabio Facchetti,Giorgio Rossi,Paolo Corradini +18 more
TL;DR: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate, which accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
Massimo Milione,Elena Ardini,Jason Christiansen,Emanuele Valtorta,Silvio Veronese,Roberta Bosotti,Alessio Pellegrinelli,Adele Testi,Filippo Pietrantonio,Giovanni Fucà,Ge Wei,Danielle Murphy,Salvatore Siena,Antonella Isacchi,Filippo de Braud +14 more
TL;DR: It is shown that this novel fusion is oncogenic and sensitive to TRKA inhibitors, and may help identifying a subset of patients able to derive benefit from treatment with entrectinib or other targeted inhibitors.